Kernal Biologics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2016

Location

Cambridge MA US

Primary Industry

Biotechnology

About

Founded in 2016 by its CEO, Yusuf Erkul, and president, Burak Yilmaz, and based in Massachusetts, US, Kernal Biologics, Inc., operates as a biotechnology company that creates mRNA therapies to cure diseases like COVID and cancer. In February 2022, Kernal Biologics, Inc., raised USD 20 million in series A funding led by returning investor Hummingbird Ventures, with participation from other returning investors Amino Collective and Civilization Ventures. Kernal Biologics uses deep learning to create mRNA therapies that will instruct cells on how to create their own medicine. The firm is currently developing mRNA technology that targets SARS-Cov-2 and opens an mRNA platform that will work on developing vaccines for COVID-19. The company plans to use the February 2022 funding to expand its mRNA 2.0 platform and support its IND for immuno-oncology candidate KR-335.

Current Investors

FoundersX Ventures, Hummingbird Ventures, Civilization Ventures

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Medical Software, Application Integration Software

Website

www.kernalbio.com

Verticals

Artificial Intelligence, HealthTech

Company Stage

Angel & Seed

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.